PPARGC1A and fatty liver disease: In a mouse model of hepatic steatosis, the PGC-1α activity was impaired, and genes involved in mitochondrial biogenesis and FAO including Cpt1a were suppressed [17,18], suggesting a therapeutic benefit for PGC-1α activation.